3-V Biosciences raises $28.5m in Series D

Oncology and infectious diseases company 3-V Biosciences has raised $28.5m in a Series D venture round co-led by NEA, Kleiner Perkins, Rock Springs Capital Management and Ally Bridge Group.

Oncology and infectious diseases company 3-V Biosciences has raised $28.5m in a Series D venture round co-led by NEA, Kleiner Perkins, Rock Springs Capital Management and Ally Bridge Group.

Proceeds from the capital infusion will enable 3-V to advance development of its experimental oncology drug TVB-2640, an oral fatty...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category